Literature DB >> 23051711

Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.

Sari Nakao1, Seiichiro Mori, Kazunari Kondo, Koji Matsumoto, Hiroyuki Yoshikawa, Tadahito Kanda.   

Abstract

Antisera induced by immunization of rabbits with the synthetic peptide P56/75, which has the amino acid (aa) sequence from aa56 to aa75 of HPV16 L2, neutralize pseudovirions and raft-virions of multiple high-risk HPV types, indicating that cross-neutralization epitopes are present in the aa56-75 region. We generated two mouse monoclonal antibodies (MAb): MAb13B and MAb24B recognizing the regions of aa64-73 and aa58-64, respectively. The neutralization assay using pseudovirions of HPV16, 18, 31, 33, 35, 51, 52 and 58 showed that MAb13B neutralized HPV16, 18, and 51, and MAb24B neutralized all the types tested. The mixture of MAb13B and MAb24B neutralized HPV16, 18, and 51 pseudovirions more efficiently than each of the MAbs alone. The data indicate that there are at least two cross-neutralization epitopes in the aa56-75 region and that an antigen capable of presenting the two cross-neutralization epitopes would be a good vaccine candidate for a broad-spectrum of HPVs.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23051711     DOI: 10.1016/j.virol.2012.09.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  HPV vaccines: Global perspectives.

Authors:  Gaurav Gupta; Reinhard Glueck; Pankaj R Patel
Journal:  Hum Vaccin Immunother       Date:  2017-03-31       Impact factor: 3.452

2.  Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Authors:  Joshua W Wang; Subhashini Jagu; Wai-Hong Wu; Raphael P Viscidi; Anne Macgregor-Das; Jessica M Fogel; Kihyuck Kwak; Sai Daayana; Henry Kitchener; Peter L Stern; Patti E Gravitt; Cornelia L Trimble; Richard B S Roden
Journal:  Clin Vaccine Immunol       Date:  2015-05-13

3.  Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.

Authors:  S M Bywaters; S A Brendle; J Biryukov; J W Wang; J Walston; J Milici; R B Roden; C Meyers; N D Christensen
Journal:  Virology       Date:  2018-08-28       Impact factor: 3.616

4.  Potential cross-reactivity of monoclonal antibodies against clinically relevant mycobacteria.

Authors:  K Flores-Moreno; J S Celis-Meneses; D M Meneses-Ruiz; A I Castillo-Rodal; P Orduña; B A Montiel; Y López-Vidal
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

5.  Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccine.

Authors:  Hanna Seitz; Tatiana Dantheny; Frank Burkart; Simone Ottonello; Martin Müller
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

Review 6.  L2, the minor capsid protein of papillomavirus.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Virology       Date:  2013-05-17       Impact factor: 3.616

7.  Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.

Authors:  Mathieu Boxus; Michel Fochesato; Agnès Miseur; Emmanuel Mertens; Najoua Dendouga; Sarah Brendle; Karla K Balogh; Neil D Christensen; Sandra L Giannini
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

8.  Human papillomavirus vaccination: current indications and future directions.

Authors:  Leda Gattoc; Navya Nair; Kevin Ault
Journal:  Obstet Gynecol Clin North Am       Date:  2013-05-10       Impact factor: 2.844

9.  Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.

Authors:  Joshua W Wang; Wai Hong Wu; Tsui-Chin Huang; Margaret Wong; Kihyuck Kwak; Keiko Ozato; Chien-Fu Hung; Richard B S Roden
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

10.  Optimization of multimeric human papillomavirus L2 vaccines.

Authors:  Subhashini Jagu; Kihyuck Kwak; Balasubramanyam Karanam; Warner K Huh; Vijayarangam Damotharan; Sudha V Chivukula; Richard B S Roden
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.